EMICIZUMAB DATA
Additional Topics
Select publications and scientific data presentations with the strongest and most relevant data are provided below.
Hemophilia A With Other Coexisting Health Conditions
Emicizumab Is Efficacious in People With Hemophilia A With Comorbidities Aged ≥50 Years: Analysis of 4 Phase III Trials
Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. Res Pract Thromb Haemost. 2024;8(3):102405.
Emicizumab in People With Moderate or Mild Haemophilia Aged ≥40 Years, With and Without Comorbidities
Jiménez-Yuste V, Tzeng E, Lim E, et al. Presented at EAHAD; February 6-9, 2024.
Bone Health and Physical Activity
TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab
Amano K, Fujii T, Sawada A, et al. Haemophilia. 2025 Jun 18. doi: 10.1111/hae.70070.
Health-Related Quality of Life (HRQoL), Physical Activity (PA), and Joint Health in People With Severe Haemophilia A (PwSHA) and a Bleeding Phenotype Receiving Emicizumab – Results From the HemiNorth 2 Study
Astermark J, Ranta S, Estesson LM, et al. Presented at EAHAD; February 4-7, 2025.
Effect of Emicizumab Prophylaxis on Bone and Joint Health Markers in People With Haemophilia A Without Factor VIII Inhibitors in the HAVEN 3 Study
Kiialainen A, Niggli M, Kempton C, et al. Haemophilia. 2022;28(6):1033–1043.
Hemophilia A and Mortality
Mortality in Congenital Hemophilia A - A Systematic Literature Review
Hay CRM, Nissen F, and Pipe SW. J Thromb Haemost. 2021;19(Suppl 1):6–20.
Establishment of a Framework for Assessing Mortality in Persons With Congenital Hemophilia A and Its Application to an Adverse Event Reporting Database
Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. J Thromb Haemost. 2021;19(Suppl 1):21–31.
Application of a Hemophilia Mortality Framework to the Emicizumab Global Safety Database
Peyvandi F, Mahlangu JN, Pipe SW, et al. J Thromb Haemost. 2021;19(Suppl 1):32–41.
A Systematic Review of Mortality Statistics and Causes of Death in People With Congenital Hemophilia A (PwcHA)
Hay C, Nissen F, and Pipe S. Presented at NHF; August 1-8, 2020.
A Contemporary Framework for Understanding Mortality in People With Congenital Hemophilia A (PwcHA)
Pipe S, Kruse-Jarres R, Mahlangu J, et al. Presented at NHF; August 1-8, 2020.
An Analysis of Fatalities in Persons With Congenital Hemophilia A Reported in the FDA Adverse Event Reporting System (FAERS) Database
De Ford C, Kuebler P, Shang A, et al. Presented at NHF; August 1-8, 2020.
Impact of Inhibitors on Hemophilia A Mortality in the United States
Walsh CE, Soucie JM, Miller CH, et al. Am J Hematol. 2015;90:400–405.
Real-World Experience
Journal articles describing efficacy, safety, or surgical outcomes related to emicizumab in ≥50 patients in a real-world registry setting.
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
Fischer K, Lassila R, Peyvandi F, et al. Haemophilia. 2025 Apr 2. doi: 10.1111/hae.70039.
Bleeding Control Improves After Switching to Emicizumab: Real-World Experience of 177 Children in the PedNet Registry
van der Zwet K, de Kovel M, Motwani J, et al. Haemophilia. 2024;30(3):685–692.
Intraindividual Bleeding Outcomes in Patients With Hemophilia A on Emicizumab Prophylaxis in Australia
Ramanan R, Parikh S, Aung LL, et al. Blood Vessels Thromb Hemost. 2024;1(1):100005.
Emicizumab Prophylaxis in Haemophilia A With Inhibitors: Three Years Follow-Up From the UK Haemophilia Centre Doctors' Organisation (UKHCDO)
Wall C, Xiang H, Palmer B, et al. Haemophilia. 2023;29(3):743–752.